Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo inhaler Clear all

Conditions: Immune System
Interventions: Essential oil blend, Placebo; Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 20 Years to 65 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: COPD, Chronic Obstructive Pulmonary Disease
Interventions: CHF 5259, Placebo, Tiotropium Bromide 18 µg Inhalation Capsule; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 112
States / cities: Birmingham, Alabama • Dothan, Alabama • Montgomery, Alabama + 99 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 69
States / cities: Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more

Conditions: Exercise-Induced Bronchoconstriction (EIB)
Interventions: Albuterol Spiromax, Placebo Spiromax; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 6
States / cities: San Diego, California • Denver, Colorado • Wheaton, Maryland + 2 more

Conditions: Exercise-induced Bronchospasm
Interventions: arformoterol, formoterol, placebo; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 12 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Pulmonary Artery Hypertension
Interventions: GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more

Conditions: Asthma
Interventions: Glycopyrronium MDI, Serevent Diskus 50 μg, Placebo; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 43
States / cities: Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Part A: RPL554, Part B: RPL554, Placebos; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Union, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 2,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF/GW642444 Inhalation Powder, FF Inhalation Powder, GW642444 Inhalation Powder, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,031 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 47
States / cities: Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 42 more

Conditions: Influenza
Interventions: 20 mg laninamivir octanoate, Placebo, 40 mg laninamivir octanoate; Drug
Lead sponsor: Biota Scientific Management Pty Ltd; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 28
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more

Conditions: Asthma
Interventions: Placebo twice daily, Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily, Olodaterol high daily dose once daily and placebo, Olodaterol medium daily dose once daily and placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 12
States / cities: Huntington Beach, California • Centennial, Colorado • Wheat Ridge, Colorado + 9 more

Conditions: Asthma
Interventions: Ciclesonide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Asthma
Interventions: Albuterol, Placebo, Proventil® HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: Huntington Beach, California • Palmdale, California • Paramount, California + 10 more

Conditions: COPD
Interventions: indacaterol, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 6
States / cities: Fullerton, California • Saint Charles, Missouri • Charlotte, North Carolina + 3 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Olodaterol (BI 1744), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 28
States / cities: Mobile, Alabama • Wheat Ridge, Colorado • Waterbury, Connecticut + 23 more

Conditions: Persistent Asthma
Interventions: Indacaterol, Placebo to Indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 21
States / cities: Anniston, Alabama • Cypress, California • Fresno, California + 16 more

Conditions: Asthma
Interventions: CVT-301 (levodopa inhalation powder), Carbidopa, Placebo; Drug · Other
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas

Conditions: Asthma
Interventions: Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 22
States / cities: Encinitas, California • Lancaster, California • Los Angeles, California + 19 more

Conditions: Persistent Asthma
Interventions: Beclomethasone Dipropionate 640, Placebo, Beclomethasone dipropionate via 320 mcg BAI, albuterol/salbutamol, Beclomethasone dipropionate via 320 mcg MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 75
States / cities: Peoria, Arizona • Downey, California • Huntington Beach, California + 59 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires; Device · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 18
States / cities: Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more

Search by objective public record fields.

Aromatherapy for Upper Respiratory Health

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)

Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Albuterol HFA MDI in Pediatric Participants With Asthma

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

12 / 48 wk Pivotal PFT vs PBO in COPD II

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)